Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,540.00    9.00 (0.59%)
Bid:
1,535.00
Ask:
1,536.00
Spread: 1.00 (0.065%)
Market Cap: £3.24b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

26 Sep 2016 10:18

RNS Number : 8036K
Hikma Pharmaceuticals Plc
26 September 2016
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.49%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.82%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-executive Director/ PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 7.95%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs, Company Secretary, Responsible for releasing this announcement

26 September 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDCLBDBGLL
Date   Source Headline
10th Jun 20145:13 pmRNSTotal Voting Rights
29th May 20149:45 amRNSDirector/PDMR Shareholding
29th May 20149:40 amRNSDirector/PDMR Shareholding
28th May 201412:00 pmRNSAcquisition
27th May 20149:53 amRNSDirector/PDMR Shareholding
15th May 20143:05 pmRNSResults of AGM
15th May 20147:00 amRNSInterim Management Statement
6th May 20141:03 pmRNSDirector/PDMR Shareholding
17th Apr 20144:41 pmRNSAnnual Information Update
14th Apr 20145:28 pmRNSDirector/PDMR Shareholding
7th Apr 20145:28 pmRNSBlocklisting Interim Review
7th Apr 20144:27 pmRNSTotal Voting Rights
2nd Apr 20147:00 amRNSSuccessful resolution to US FDA warning letter
24th Mar 201410:23 amRNSDirector/PDMR Shareholding
12th Mar 20147:10 amRNSDirectorate Change
12th Mar 20147:00 amRNSFinal Results
27th Feb 20142:35 pmRNSNotification of major interests in shares
21st Feb 201410:24 amRNSBlock Listing of Shares
14th Feb 20147:00 amRNSTrading Statement
30th Dec 20139:50 amRNSDirector/PDMR Shareholding
20th Dec 20134:23 pmRNSDirector/PDMR Shareholding
20th Dec 20131:58 pmRNSDirector/PDMR Shareholding
16th Dec 20137:00 amRNSTotal Voting Rights
13th Dec 20137:00 amRNSHolding(s) in Company
20th Nov 20137:00 amRNSRe Agreement
11th Nov 20134:55 pmRNSDirector/PDMR Shareholding
8th Nov 20133:04 pmRNSDirector/PDMR Shareholding
8th Nov 20137:00 amRNSInterim Management Statement
25th Oct 20134:13 pmRNSDirector/PDMR Shareholding
23rd Oct 201311:40 amRNSHolding(s) in Company
18th Oct 20134:55 pmRNSDirector/PDMR Shareholding
4th Oct 20132:01 pmRNSDividend Declaration
1st Oct 201311:27 amRNSBlocklisting Interim Review
1st Oct 201311:22 amRNSTotal Voting Rights
18th Sep 20137:00 amRNSHikma entering Ethiopian pharmaceutical market
2nd Sep 20133:06 pmRNSTransaction in Own Shares
29th Aug 201311:10 amRNSTransaction in Own Shares
21st Aug 20137:00 amRNSInterim Results
31st Jul 20133:41 pmRNSDirector/PDMR Shareholding
19th Jul 20139:40 amRNSTotal Voting Rights
8th Jul 20137:00 amRNSTrading Statement
5th Jul 20134:21 pmRNSHolding(s) in Company
1st Jul 20137:00 amRNSSigning of Exclusive Agreement with Theravance
20th Jun 20133:16 pmRNSDirector/PDMR Shareholding
3rd Jun 201311:24 amRNSTotal Voting Rights
28th May 20135:24 pmRNSHolding(s) in Company
23rd May 20134:59 pmRNSDirector/PDMR Shareholding
21st May 20133:36 pmRNSDirector/PDMR Shareholding
20th May 20139:42 amRNSDirector/PDMR Shareholding
16th May 20133:32 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.